Revance Therapeutics Inc has a consensus price target of $15, established from looking at the 54 latest analyst ratings. The last 3 analyst ratings were released from Goldman Sachs, HC Wainwright & Co., and Piper Sandler on March 1, 2024, February 29, 2024, and February 29, 2024. With an average price target of $13.67 between Goldman Sachs, HC Wainwright & Co., and Piper Sandler, there's an implied 177.78% upside for Revance Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/01/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 82.93% | Goldman Sachs | Chris Shibutani | $8 → $9 | Maintains | Neutral | Get Alert |
02/29/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 143.9% | HC Wainwright & Co. | Douglas Tsao | → $12 | Reiterates | Buy → Buy | Get Alert |
02/29/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 306.5% | Piper Sandler | David Amsellem | $42 → $20 | Maintains | Overweight | Get Alert |
02/29/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 265.85% | Needham | Serge Belanger | $20 → $18 | Maintains | Buy | Get Alert |
02/23/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 143.9% | HC Wainwright & Co. | Douglas Tsao | $15 → $12 | Maintains | Buy | Get Alert |
01/29/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 103.25% | Barclays | Balaji Prasad | $35 → $10 | Maintains | Overweight | Get Alert |
01/29/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 82.93% | Mizuho | Vamil Divan | $16 → $9 | Downgrade | Buy → Neutral | Get Alert |
01/09/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 306.5% | Needham | Serge Belanger | $25 → $20 | Maintains | Buy | Get Alert |
01/09/2024 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 62.6% | Goldman Sachs | Chris Shibutani | $30 → $8 | Downgrade | Buy → Neutral | Get Alert |
11/22/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 225.2% | Mizuho | Uy Ear | $35 → $16 | Maintains | Buy | Get Alert |
11/09/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 753.66% | Piper Sandler | David Amsellem | $44 → $42 | Maintains | Overweight | Get Alert |
11/09/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 408.13% | Needham | Serge Belanger | $35 → $25 | Maintains | Buy | Get Alert |
11/06/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 204.88% | HC Wainwright & Co. | Douglas Tsao | $41 → $15 | Maintains | Buy | Get Alert |
10/23/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 611.38% | Barclays | Balaji Prasad | $40 → $35 | Maintains | Overweight | Get Alert |
10/11/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 143.9% | Morgan Stanley | Terence Flynn | $25 → $12 | Maintains | Equal-Weight | Get Alert |
09/21/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 570.73% | Goldman Sachs | Chris Shibutani | $38 → $33 | Maintains | Buy | Get Alert |
09/20/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 794.31% | Piper Sandler | David Amsellem | $50 → $44 | Maintains | Overweight | Get Alert |
09/20/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 733.33% | HC Wainwright & Co. | Douglas Tsao | → $41 | Reiterates | Buy → Buy | Get Alert |
09/20/2023 | RVNC | Buy Now | Revance Therapeutics | $4.92 | 611.38% | Needham | Serge Belanger | $40 → $35 | Maintains | Buy | Get Alert |
The latest price target for Revance Therapeutics (NASDAQ: RVNC) was reported by Goldman Sachs on March 1, 2024. The analyst firm set a price target for $9.00 expecting RVNC to rise to within 12 months (a possible 82.93% upside). 31 analyst firms have reported ratings in the last year.
The latest analyst rating for Revance Therapeutics (NASDAQ: RVNC) was provided by Goldman Sachs, and Revance Therapeutics maintained their neutral rating.
The last upgrade for Revance Therapeutics Inc happened on August 16, 2023 when Exane BNP Paribas raised their price target to $20. Exane BNP Paribas previously had an underperform for Revance Therapeutics Inc.
The last downgrade for Revance Therapeutics Inc happened on January 29, 2024 when Mizuho changed their price target from $16 to $9 for Revance Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revance Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revance Therapeutics was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
While ratings are subjective and will change, the latest Revance Therapeutics (RVNC) rating was a maintained with a price target of $8.00 to $9.00. The current price Revance Therapeutics (RVNC) is trading at is $4.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.